Abstract: The object of the invention is a bowed instrument comprising a body (2) and a neck (1), the upper face of the body (2) being the top plate (4), at the bottom of which a tailpiece is disposed secured to the bottom of the instrument, the strings (14) being disposed in a tensioned state, supported from below by a bridge, between the tailpiece and the scroll (8) of the neck (1). The bowed instrument according to the invention comprises a tailpiece (16) that is adapted to retain the bottom portion of the strings (14), has an arcuate triangular shape, has an asymmetrically shaped body made of a multilayered material, and is rounded along the periphery of its body, wherein bores (20) adapted for receiving the strings (14) are disposed at the bottom corner (a) and along the arced portion (9) extending between the two upper corners (b, c) thereof.

Abstract: The object of the invention is a bowed instrument comprising a body (2) and a neck (1), the upper face of the body (2) being the top plate (4), at the bottom of which a tailpiece is disposed secured to the bottom of the instrument, the strings (14) being disposed in a tensioned state, supported from below by a bridge, between the tailpiece and the scroll (8) of the neck (1). The bowed instrument according to the invention comprises a tailpiece (16) that is adapted to retain the bottom portion of the strings (14), has an arcuate triangular shape, has an asymmetrically shaped body made of a multilayered material, and is rounded along the periphery of its body, wherein bores (20) adapted for receiving the strings (14) are disposed at the bottom corner (a) and along the arced portion (9) extending between the two upper corners (b, c) thereof.

Abstract: A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents.

Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

Abstract: This invention provides a method for a method for optimizing the regimen for the administration of chemotherapeutic agents. The method comprises administration of a selenium compound to an individual, monitoring the modulation of tumor vessel maturation (TVM) to identify an optimal time for administration of a chemotherapeutic agent. This invention also provides a method to determine whether or not a tumor is likely to be a responder to chemotherapy. The method comprises administration of a selenium compound to an individual and determining whether or not an increase in TVM is observed. An increased TVM following administration of selenium is an indication that the tumor will likely respond the chemotherapy.

Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

Abstract: The present invention discloses a method for reducing alopecia and bladder toxicity associated with the anti-cancer agent cyclophosphamide. The method comprises administering to an individual, in need of such a treatment, cyclophosphamide and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Abstract: A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents.

Abstract: This invention provides a method for a method for optimizing the regimen for the administration of chemotherapeutic agents. The method comprises administration of a selenium compound to an individual, monitoring the modulation of tumor vessel maturation (TVM) to identify an optimal time for administration of a chemotherapeutic agent. This invention also provides a method to determine whether or not a tumor is likely to be a responder to chemotherapy. The method comprises administration of a selenium compound to an individual and determining whether or not an increase in TVM is observed. An increased TVM following administration of selenium is an indication that the tumor will likely respond the chemotherapy.

Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

Abstract: The present invention relates to the use of cotton rats and Syrian hamsters as models for adenoviral gene therapy. In particular, the models are directed to the examination of the ability of various replicative, non-replicative and conditionally-replicative adenovirus vectors to treat cancer.

Abstract: Novel adenovirus vectors which overexpress an adenovirus death protein and which are replication-competent in and, preferably, replication-restricted to cells expressing telomerase. One embodiment provides for efficient destruction and removal of viral-infected host cells expressing telomerase. Still further, another embodiment provides for additional restriction and safety by disrupting E1A's ability to bind p300 and/or members of the Rb family members. Compositions of the novel vectors and methods for promoting death of cells expressing telomerase with these vectors are also disclosed.

Abstract: There is provided an assay suitable for the typing of bacterial strains. In the assay a predetermined amount of phage is combined with a bacterial isolate of unknown strain, the mixture being located in a suitable container. The mixture of phage and bacteria is conveniently held in a liquid or semi-liquid medium facilitating interaction of the two species. The extent of bacterial growth in the presence of the phage is measured by conventional means, preferably by means of an OD reading. Desirably the phage is retained in the selected container, which is conveniently a micro-titer plate, through use of a fixant such as 5% gelatin.

Abstract: Novel adenovirus vectors which overexpress an adenovirus death protein and which are replication-competent in and, preferably, replication-restricted to cells expressing telomerase. One embodiment provides for efficient destruction and removal of viral-infected host cells expressing telomerase. Still further, another embodiment provides for additional restriction and safety by disrupting E1A's ability to bind p300 and/or members of the Rb family members. Compositions of the novel vectors and methods for promoting death of cells expressing telomerase with these vectors are also disclosed.